A systematic review and network meta-analysis of the efficacy and safety of third-line and over third-line therapy after imatinib and TKI resistance in advanced gastrointestinal stromal tumor

被引:2
|
作者
Xiao, Xianhao [1 ]
Yuan, Weiye [1 ]
Wang, Chong [1 ]
Song, He [1 ]
机构
[1] First Hosp China Med Univ, Shenyang, Liaoning, Peoples R China
关键词
gastrointestinal stromal tumor; precise targeted therapy; refractory GIST; network meta-analysis; systematic review; PHASE-III; KINASE INHIBITOR; TYROSINE KINASE; SUPPORTIVE CARE; OPEN-LABEL; MULTICENTER; SUNITINIB; KIT; MESYLATE; TRIAL;
D O I
10.3389/fphar.2022.978885
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tyrosine kinase inhibitors (TKIs) have greatly improved the prognosis of unresectable and metastatic gastrointestinal stromal tumors (GISTs) in the last two decades. Imatinib and sunitinib are recommended as first-line and second-line therapies, respectively. However, there is a lack of precision therapy for refractory GISTs regarding therapy after imatinib and sunitinib. We comprehensively searched electronic databases, including PubMed, EMBASE, Web of Science, Cochrane Library, and ClinicalTrials, from inception to October 2022. Randomized controlled trials featuring comparisons with third-line or over third-line therapies against GISTs were eligible. The primary outcome was progression-free survival (PFS). All network calculations were performed using random effect models, and the ranking of regimens were numerically based on the surface under the cumulative ranking (SUCRA) statistics. A total of seven studies were eligible for inclusion in this network meta-analysis. After analysis, ripretinib was ranked at the top in progression-free survival (PFS), overall survival (OS), and disease control rate (DCR) (SUCRA statistics: 83.1%, 82.5%, and 86.5%, respectively), whereas nilotinib and pimitespib presented better tolerability (SUCRA statistics: 64.9% and 63.8%, respectively). We found that regorafenib seemed more reliable for clinical administration, and ripretinib showed good effectiveness for the over third-line therapy. Precise targeted therapy is a critical direction for the future treatment of GIST, and more high-quality studies of new agents are expected.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Efficacy and safety of anlotinib as a third-line treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials
    Zha, Bowen
    Zhang, Yuxin
    Yang, Runzi
    Kamili, Muladili
    [J]. ONCOLOGY LETTERS, 2022, 24 (01)
  • [32] A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor
    Pantaleo, Maria A.
    Heinrich, Michael C.
    Italiano, Antoine
    Valverde, Claudia
    Schoffski, Patrick
    Grignani, Giovanni
    Reyners, Anna K. L.
    Bauer, Sebastian
    Reichardt, Peter
    Stark, Daniel
    Berhanu, Ghimja
    Brandt, Ulrike
    Stefanelli, Tommaso
    Gelderblom, Hans
    [J]. BMC CANCER, 2022, 22 (01)
  • [33] Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer
    Ozaslan, Ersin
    Topaloglu, Ulas Serkan
    Inanc, Mevlude
    Erdem, Umut Gokmen
    Demir, Hacer
    Arpaci, Erkan
    Seker, Mehmet Metin
    Karaaga, Mustafa
    Kiziltepe, Melih
    Eker, Baki
    Ozkan, Metin
    [J]. JOURNAL OF BUON, 2017, 22 (04): : 863 - 868
  • [34] A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor
    Maria A. Pantaleo
    Michael C. Heinrich
    Antoine Italiano
    Claudia Valverde
    Patrick Schöffski
    Giovanni Grignani
    Anna K. L. Reyners
    Sebastian Bauer
    Peter Reichardt
    Daniel Stark
    Ghimja Berhanu
    Ulrike Brandt
    Tommaso Stefanelli
    Hans Gelderblom
    [J]. BMC Cancer, 22
  • [35] Third-line systemic treatment versus supportive care for advanced/ metastatic gastric cancer: A systematic review and meta-analysis.
    Chan, Wing-lok
    Yuen, Kwok-keung
    Siu, Steven Wai-kwan
    Lam, Ka-On
    Kwong, Dora Lai Wan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [36] A systematic review and network meta-analysis of post-imatinib therapy in advanced gastrointestinal stromal tumour
    Shah, K.
    Chan, K. K. W.
    Ko, Y. J.
    [J]. CURRENT ONCOLOGY, 2017, 24 (06) : E531 - E539
  • [37] Safety and continuity of second- and third-line therapy with paclitaxel or irinotecan for advanced and recurrent gastric cancer
    Kimura, Michio
    Usami, Eiseki
    Kanematsu, Tetsufumi
    Iwai, Mina
    Yoshimura, Tomoaki
    Mori, Hiromi
    Sugiyama, Tadashi
    Teramachi, Hitomi
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (03) : 466 - 472
  • [38] Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment A meta-analysis
    Zhang, Zhenan
    Jiang, Tao
    Wang, Wensheng
    Piao, Daxun
    [J]. MEDICINE, 2017, 96 (48)
  • [39] COST-EFFECTIVENESS ANALYSIS OF THE THIRD-LINE TREATMENT OF REGORAFENIB FOR METASTATIC OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS IN CHINA
    Wang, Y.
    Rui, M.
    Cao, Y. D.
    Fei, Z.
    Ma, A. X.
    Li, H. C.
    [J]. VALUE IN HEALTH, 2021, 24 : S28 - S28
  • [40] Role of Systemic Treatment for Advanced/Metastatic Gastric Carcinoma in the Third-Line Setting: A Bayesian Network Analysis
    Pan, Wen-Tao
    Zhou, Su-Na
    Pan, Meng-Xian
    Luo, Qiu-Yun
    Zhang, Lin
    Yang, Da-Jun
    Qiu, Miaozhen
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10